Evidence map›Paper›PMID 41712059›Full record

ArticleInternational ophthalmology2026

Loading dose and 12-month outcomes in treatment-naïve patients with neovascular age-related macular degeneration treated with faricimab, with AI-based analysis of fluid dynamics.

Mickael Barbosa, Nicolò Bartolomeo, Yannic Pannatier Schuetz, Anna C Nascimbeni, Daniela Gallo Castro, Mamadou Pathé Barry, Aude Ambresin

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mickael BarbosaSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Avenue du Servan 38, 1006, Lausanne, Switzerland.
Nicolò BartolomeoSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Avenue du Servan 38, 1006, Lausanne, Switzerland.
Yannic Pannatier SchuetzSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Avenue du Servan 38, 1006, Lausanne, Switzerland.
Anna C NascimbeniSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Avenue du Servan 38, 1006, Lausanne, Switzerland.
Daniela Gallo CastroSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Avenue du Servan 38, 1006, Lausanne, Switzerland.
Mamadou Pathé BarrySwiss Visio Retina Research Center, Swiss Visio Montchoisi, Avenue du Servan 38, 1006, Lausanne, Switzerland.
Aude AmbresinSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Avenue du Servan 38, 1006, Lausanne, Switzerland. aambresinsvrrc@swissvisio.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the effects of loading dose and 12 months of faricimab treatment on visual function, retinal anatomy, and fluid dynamics in a real-world cohort of treatment-naïve patients with neovascular age-related macular degeneration (nAMD).

methodsPatients received intravitreal faricimab 6 mg monthly (to Month 4) followed by personalized treat-and-extend regimens allowing 4-week interval adjustments. Best-corrected visual acuity (BCVA), retinal anatomy, and fluid dynamics (evaluated using an artificial intelligence-based automated fluid quantification system) were assessed monthly to Month 4, then at Months 6, 9, and 12.

resultsFifty-one patients (57 study eyes; mean [SD] BCVA: 66.5 [13.4] letters; mean [SD] central retinal thickness [CRT]: 340.7 [84.7] μm at baseline) were enrolled. Significant improvements in mean BCVA (+ 3.3 letters; P < 0.001) and CRT (- 70.5 μm; P < 0.001) were observed by Month 4. Maximal pigment epithelium detachment (PED) height reduced significantly from baseline to Month 4. Improvements were maintained to Month 12. Intra- and subretinal fluid and PED volumes were significantly reduced versus baseline at all time points. At Month 12, 73.3% of patients were on treatment intervals of 12 weeks or longer. Three adverse events were observed, including one mild intraocular inflammation.

conclusionTreatment with faricimab resulted in rapid and sustained functional and anatomical improvements in treatment-naïve nAMD.

Indexed as

Visual AcuityWet Macular DegenerationAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, BispecificDose-Response Relationship, DrugFemaleFluorescein AngiographyFollow-Up StudiesHumansHydrodynamicsIntelligent SystemsIntravitreal InjectionsMaleTime FactorsAngiogenesis InhibitorsAntibodies, BispecificfaricimabAI-based analysisFaricimabFluid dynamicsLoading doseNeovascular age-related macular degenerationRetinal fluidTreatment-naïve

Identifiers

PMID41712059

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.